Hisashi Tsurumi
Hashima, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 124 publications
Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: July 30, 2026
Transient acquired thrombotic thrombocytopenic purpura developed during bortezomib, lenalidomide, and dexamethasone therapy for multiple myeloma
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: July 08, 2026
HIV-Associated Diffuse Large B-Cell Lymphoma Treated With Outpatient Pola-R-CHP Without Antiretroviral Therapy Modification: A Case Report.
Journal: Case reports in infectious diseases
Published: January 26, 2026
Real-world outcome and dose intensity of Pola-R-CHP versus R-CHOP/R-THP-COP in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective cohort study.
Journal: BMC cancer
Published: October 29, 2025
Clinical Impact of the Geriatric Nutritional Risk Index on Chemotherapy-Related Adverse Events in Diffuse Large B-Cell Lymphoma: A Multicenter Study.
Journal: Nutrients
Published: October 16, 2025
A Comparison of the Risk of Viral Load Blips in Human Immunodeficiency Virus Patients on Two-Drug Versus Three-Drug Antiretroviral Regimens.
Journal: Infectious disease reports
Published: August 09, 2025
Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).
Journal: International journal of hematology
Published: July 24, 2025
Impact of a nudge-based intervention on hand soap usage in a Japanese Hospital: interrupted time series analysis.
Journal: Infection prevention in practice
Published: July 15, 2025
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.
Journal: Annals of hematology
Published: July 13, 2025
Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Journal: Hematological oncology
Published: May 21, 2025
Impact of the acute national blood culture bottle shortage on the two-set blood culture rate in a single center in Japan: Insights from an interrupted time-series analysis.
Journal: Infection prevention in practice
Published: May 15, 2025
Last Updated: 09/26/2026